

BMJ Open

Perceptions of risk and predictive testing held by the first degree relatives of patients with rheumatoid arthritis in England, Austria and Germany: a qualitative study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-010555.R1
Article Type:	Research
Date Submitted by the Author:	n/a
Complete List of Authors:	Stack, Rebecca; Nottingham Trent University , Division of Psychology Stoffer, Michaela ; 4. University of Applied Sciences for Health Professionals Englbrecht, Matthias; University of Erlangen-Nuremberg, Department of Internal Medicine 3 and Institute of Clinical Immunology Mosor, Erika; Department of Internal Medicine III Medical University of Vienna, Division of Rheumatology Falahee, Marie; University of Birmingham , Institute of Inflammation and Ageing Simons, Gwenda; University of Birmingham , Institute of Inflammation and Ageing Smolen, Josef; Department of Internal Medicine III Medical University of Vienna, Division of Rheumatology Schett, Georg; University of Erlangen, Rheumatology Buckley, Chris; University of Birmingham, Institute of Inflammation and Ageing Kumar, Kanta; University of Manchester, School of Nursing Hansson, Mats; Uppsala University Hueber, Axel; University of Erlangen, Department of Internal Medicine III and Institute for Clinical Immunology Stamm, Tanja; Department of Internal Medicine III Medical University of Vienna, Division of Rheumatology Raza, Karim; University of Birmingham, Institute of Inflammation and Ageing
Primary Subject Heading:	Rheumatology
Secondary Subject Heading:	Genetics and genomics, Qualitative research, Patient-centred medicine
Keywords:	Risk, Genetics < TROPICAL MEDICINE, Rheumatology < INTERNAL MEDICINE, Rheumatoid Arthritis, QUALITATIVE RESEARCH

SCHOLARONE™
Manuscripts

Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups

Table 1

Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist

No	Item	Guide questions/description	
Domain 1:			
Research team and reflexivity			
Personal Characteristics			
1.	Interviewer /facilitator	Which author/s conducted the interview or focus group?	RJS, KK, ME, AH, MS, EM
2.	Credentials	What were the researcher's credentials? <i>E.g. PhD, MD</i>	RJS, KK, ME, AH, MS highest qualifications are PhD, EM highest qualification is MSc
3.	Occupation	What was their occupation at the time of the study?	RJS, KK, ME, MS, EM are research fellows AH is a rheumatologist
4.	Gender	Was the researcher male or female?	Mixture of male and female
5.	Experience and training	What experience or training did the researcher have?	All have extensive experience and training
Relationship with participants			
6.	Relationship established	Was a relationship established prior to study commencement?	Invitation letters were sent, participants were spoken to over the phone and before the interview commenced participants were given an overview of the research study.
7.	Participant knowledge of the interviewer	What did the participants know about the researcher? <i>e.g. personal goals, reasons for doing the research</i>	Participants were given participant information sheets, and given a verbal introduction to the study, its aims and the procedure.
8.	Interviewer characteristics	What characteristics were reported about the interviewer/facilitator? <i>e.g. Bias, assumptions, reasons</i>	The interviewers were from a range of backgrounds including medicine, psychology and social

No	Item	Guide questions/description <i>and interests in the research topic</i>	sciences.
Domain 2: study design			
Theoretical framework			
9.	Methodological orientation and Theory	What methodological orientation was stated to underpin the study? <i>e.g. grounded theory, discourse analysis, ethnography, phenomenology, content analysis</i>	Yes, thematic analysis
Participant selection			
10.	Sampling	How were participants selected? <i>e.g. purposive, convenience, consecutive, snowball</i>	Convenience
11.	Method of approach	How were participants approached? <i>e.g. face-to-face, telephone, mail, email</i>	Mail
12.	Sample size	How many participants were in the study?	34
13.	Non-participation	How many people refused to participate or dropped out? Reasons?	None participation rates across the centres were problematic to calculate accurately. Main reasons for not participating were difficulties in arranging suitable times and locations for interviews.
Setting			
14.	Setting of data collection	Where was the data collected? <i>e.g. home, clinic, workplace</i>	Clinical and academic settings.
15.	Presence of non-participants	Was anyone else present besides the participants and researchers?	Interviews were conducted on a one-to-one basis.
16.	Description of sample	What are the important characteristics of the sample? <i>e.g. demographic data, date</i>	The characteristics of the sample are presented in the tables contained within the paper
Data collection			
17.	Interview guide	Were questions, prompts,	Yes, the interviews were

No	Item	Guide questions/description	
		guides provided by the authors? Was it pilot tested?	semi-structured
18.	Repeat interviews	Were repeat interviews carried out? If yes, how many?	No
19.	Audio/visual recording	Did the research use audio or visual recording to collect the data?	Digital audio recorders were used.
20.	Field notes	Were field notes made during and/or after the interview or focus group?	No
21.	Duration	What was the duration of the interviews or focus group?	60-90 minutes
22.	Data saturation	Was data saturation discussed?	Yes, thematic saturations was achieved. An interactive feedback process was used were
23.	Transcripts returned	Were transcripts returned to participants for comment and/or correction?	transcripts were reflected and commented upon, however, transcripts were not feedback to participants for correct.
Domain 3: analysis and findingsz			
Data analysis			
24.	Number of data coders	How many data coders coded the data?	Five
25.	Description of the coding tree	Did authors provide a description of the coding tree?	No, instead major themes were identified.
26.	Derivation of themes	Were themes identified in advance or derived from the data?	Themes were derived from the data
27.	Software	What software, if applicable, was used to manage the data?	NVIVO
28.	Participant checking	Did participants provide feedback on the findings?	No
Reporting			
29.	Quotations presented	Were participant quotations presented to illustrate the themes / findings? Was each quotation identified? e.g.	Yes, see tables 2, 3 and 4.

No	Item	Guide questions/description <i>participant number</i>	
30.	Data and findings consistent	Was there consistency between the data presented and the findings?	Yes
31.	Clarity of major themes	Were major themes clearly presented in the findings?	Yes, major themes were identified.
32.	Clarity of minor themes	Is there a description of diverse cases or discussion of minor themes?	Yes

For peer review only

1
2
3 **Title: Perceptions of risk and predictive testing held by the first degree relatives of**
4 **patients with rheumatoid arthritis in England, Austria and Germany: a qualitative study**
5
6
7

8 **Authors**
9

10 Rebecca J Stack^{1,2}, Michaela Stoffer^{3,4}, Mathias Englbrecht⁵, Erika Mosor,³ Marie Falahee¹,
11 Gwenda Simons¹, Josef Smolen³, Georg Schett⁵, Chris D Buckley^{1,2}, Kanta Kumar⁶, Mats
12 Hansson⁷, Axel Hueber⁵, Tanja Stamm³, Karim Raza^{1,8}
13
14
15

16
17 **Affiliations**
18

- 19 1. Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University
20 of Birmingham, UK
21
22 2. Division of Psychology, Nottingham Trent University, Nottingham, UK
23
24 3. Division of Rheumatology, Department of Internal Medicine III Medical University of
25 Vienna, Austria
26
27 4. University of Applied Sciences for Health Professionals, Upper Austria, Austria
28
29 5. Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen,
30 Germany
31
32 6. School of Nursing, Faculty of Medical and Human Sciences, University of Manchester, UK
33
34 7. Centre for Research Ethics and Bioethics, Uppsala University, Sweden
35
36 8. Department of Rheumatology, Sandwell & West Birmingham Hospitals NHS Trust,
37 Birmingham, UK
38
39
40
41
42

43 **Correspondence to:**

44 Dr. Rebecca J Stack, Division of Psychology, School of Social Sciences, Nottingham Trent
45 University, NG14BU, UK rebecca.stack@ntu.ac.uk
46
47
48

49 **Keywords**

50 Risk, Rheumatoid Arthritis, First-degree Relatives, Predictive testing, Qualitative
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: The family members of rheumatoid arthritis (RA) patients are at increased risk of developing RA and are potential candidates for predictive testing. This study explored the perceptions of first degree relatives of people with RA about being at risk of RA and engaging in predictive testing.

Methods: Thirty-four first-degree relatives (siblings and off-spring) of patients with RA from the UK, Germany and Austria participated in semi-structured interviews about their perceptions of RA risk and the prospect of predictive testing. Interviews were audio-recorded, transcribed verbatim and analysed using thematic analysis.

Results: First-degree relatives were aware of their susceptibility to RA, but were unsure of the extent of their risk. When considering their future risk, some relatives were concerned about the potential impact that RA would have on their lives. Relatives were concerned that knowing their actual risk would increase their anxiety and would impact decisions about their future. Also, relatives were concerned about the levels of uncertainty associated with predictive testing. Those in favour of knowing their future risk felt that they would need additional support to understand the risk information and cope with the emotional impact of this information.

Conclusions: Identifying individuals at risk of RA may allow targeted interventions to reduce the risk and consequence of future disease; however, relatives have concerns about predictive testing and risk information. The development of strategies to quantify and communicate risk needs to take these views into account and incorporate approaches to mitigate concerns and minimize the psychological impact of risk information.

Strengths and limitations

- This study used inductive qualitative interviews to explore perceptions about risk and predictive testing in the first-degree relatives of people with RA.
- This study identified positive and negative perspectives surrounding predictive testing, and why some people at risk may not wish to be tested.

- Further research is needed to quantify the numbers of people at risk holding negative perceptions about predictive testing, and identify the behavioural implications of these beliefs.
- Communicating risk information to relatives effectively while reducing the psychological burden associated with this information, should be the focus of future interventional research.

For peer review only

Funding statement

This work was supported by European Union by within the FP7 HEALTH programme under the grant agreement FP7-HEALTH-F2-2012-305549 (EuroTEAM) and by Riksbankens Jubileumsfond (The Swedish Foundation for Humanities and Social Sciences) under Grant M13-0260:1 'Mind the Risk'.

Acknowledgements:

The authors would like to thank the EuroTEAM Patient Research Partners Panel for their involvement in this research.

Competing interests

The authors have no conflicts of interests to declare.

Contribution statement

All authors made a substantial contribution to study conception and design. RJS, MS, ME, EM, KK collected the data. RJS analysed and interpreted data. All authors were involved in drafting the article, revising it and final approval of the version of the article to be published was given by all authors.

Introduction

Rheumatoid arthritis (RA) is a chronic destructive polyarthritis. It affects approximately 1% of the population¹ and typically manifests in the 4th and 5th decades of life.²⁻⁴ Delays in diagnosis and treatment of RA are common and are associated with worse outcomes.⁵⁻⁸ Recently, an increased research effort has been directed towards the 'at risk' phases of RA, prior to the development of clinical signs of joint swelling, to identify those at risk of developing RA and to reduce this risk through the modification of environmental risk factors and pharmacological intervention.^{9;9-11}

Genetic factors contribute significantly to the risk of RA.¹² For seropositive RA at least half of the risk is conferred by genetic risk factors¹³ with recent large genetic studies having identified over 100 susceptibility loci.^{14;15} Population based epidemiological studies have shown that having a family history of RA increases the risk of RA by approximately 3-5 times,¹⁶⁻¹⁸ with the risk being higher in first degree relatives than second degree relatives.¹⁷ Furthermore, a range of environmental and life-style risk factors including occupational exposure to pollutants,¹⁹ body mass index,²⁰ periodontitis,²¹ reproductive factors,²² smoking,²³ and dietary factors²⁴⁻²⁶ contribute to the increased risk of developing RA. Some of these environmental risk factors may interact mechanistically with genetic risk factors to increase the risk of RA,²⁷ and others may have familial associations thus contributing to the familial aggregation of RA.^{28;29}

Individuals with genetic and environmental risk factors for RA may progress through a phase associated with the development of systemic autoimmunity (e.g. the development of autoantibodies such as rheumatoid factor,^{30;31} anti-citrullinated protein / peptide antibodies and anti-carbamylated protein antibodies³²) before the clinical symptoms and signs of RA manifest.⁹ It remains unclear whether there are changes detectable within the synovium during the phase of autoantibody positivity prior to the development of joint swelling.^{33;34}

Together these data suggest that information related to genotype, environmental exposures and measures of autoimmunity and inflammation may be used to predict RA development in individuals who have not yet developed clinical disease. A potential target population for

1
2
3 such testing, with a view to risk stratification and intervention to modulate risk, are the first-
4 degree relatives of individuals with RA. Indeed a number of ongoing prospective studies are
5 recruiting the first-degree relatives of patients with RA to study disease mechanisms driving
6 the switch to RA,³⁵ to develop predictive algorithms for RA, and to test interventions to
7 reduce RA risk.³⁶ Whilst considerable research effort is thus focussed on the first-degree
8 relatives of RA patients, and a qualitative study has gathered data relating to their views of
9 preventive strategies,³⁷ little is known about how such individuals view issues related to
10 their susceptibility to and risk of developing RA, and how willing they would be to be
11 assessed and tested to have this risk quantified. The present qualitative study addresses
12 these issues.
13
14
15
16
17
18
19
20
21

22 **Methods**

23
24 Ethical approval was obtained in the UK from the HumberBridge National Research Ethics
25 Committee, in Austria from the Ethics Committee of the Medical University of Vienna and in
26 Germany from the Ethics committee of the University of Erlangen-Nuremberg.
27
28
29
30
31
32

33 **Procedure**

34
35
36 Eligible participants were the first-degree relatives (offspring and siblings) of people with
37 RA. Participants were required to be at least 18 years of age and without a diagnosis of
38 inflammatory joint disease.
39
40
41
42

43
44 Patients with RA were approached during routine secondary care clinics in Birmingham
45 (United Kingdom), Erlangen (Germany) and Vienna (Austria) and were given a letter to pass
46 on to a first-degree relative of their choosing inviting them to participate in an interview
47 about risk and predictive testing for RA. Participants were recruited between October 2014
48 and October 2015. It was explained to patients that it was entirely at their discretion
49 whether to pass on the invitation letter. All research participants (i.e. the participating first-
50 degree relatives) gave written informed consent prior to interview.
51
52
53
54
55
56
57
58
59
60

1
2
3 The semi-structured interviews were guided by an interview schedule which was informed
4 by a review of the qualitative literature exploring perceptions of risk and testing in those at
5 risk of developing a chronic disease.^{38;39} The interviews aimed to assess personal
6 perceptions of risk, therefore, one-to-one interviews were conducted. In addition, an
7 international multi-disciplinary team of healthcare professionals, patient research partners
8 and researchers working on the EuroTEAM project (www.team-arthritis.eu) reviewed and
9 redrafted the interview schedule (see table 1 for sample questions from the final interview
10 schedule).

11
12
13
14
15
16
17
18
19 One-to-one Interviews were conducted at local hospitals or by telephone (for those
20 participants who had difficulty in attending the hospital for a face-to-face interview).
21 Interviews lasted between 30 and 90 minutes and were digitally audio-recorded. In the UK,
22 participants who wanted further information about arthritis were advised to contact
23 Arthritis Research UK, the National Rheumatoid Arthritis Society or the local hospital's
24 Patient Advice and Liaison Service. Participants in Austria and Germany were advised to
25 contact the local rheumatology outpatient clinic.

26
27
28
29
30
31
32
33 The interviews were transcribed verbatim. Interviews conducted in German were translated
34 into English following transcription. Transcripts were anonymised and analysed centrally in
35 Birmingham, UK, by RJS.

36 37 38 39 40 ***Analysis procedure***

41
42 Data collection and analysis were carried out in parallel to assess when thematic saturation
43 of major developing themes had been achieved. The data were analysed using a thematic
44 approach⁴⁰ facilitated by NVivo (a qualitative software programme).⁴¹ Transcripts were
45 subjected to line-by-line coding by RJS. Patient research partners blind coded three
46 transcripts to develop reliable and inclusive themes informed by multiple perspectives.
47 Discussion of the coding framework took place between researchers and patient research
48 partners. Coding categories that lacked concordance were discussed and absorbed into the
49 coding framework. The initial codes were then grouped into the most noteworthy and
50 frequently occurring categories. The core themes extracted and presented here focus on
51
52
53
54
55
56
57
58
59
60

1
2
3 perceptions of first-degree relatives about their personal risk of RA and their views on being
4 tested.
5
6

7 8 **Results** 9

10
11 Thirty-four first-degree relatives of patients with RA participated, 24 from the UK, 3 from
12 Germany and 7 from Austria. Six participants were siblings of an RA patient, 26 were the
13 adult offspring an RA patient and 2 participants had both a sibling and a parent with RA.
14 Participants were aged between 23 and 67 years (mean 39 years) and 26 (76%) were female
15 (see table 2 for participant characteristics). Quotations are presented in tables 3, 4, 5 and 6
16 and are referred to in the text using “Q” followed by the quotation code.
17
18
19
20
21
22

23 24 **Understanding of family history and genetic factors as risk factors for RA** 25

26
27 The first-degree relatives of people with RA understood that there was a hereditary
28 component to RA (Q1), and often used the word “genetic” to describe the cause of their
29 increased risk (Q2). First-degree relatives (from here on referred to as “relatives”)
30 recognised that they were more susceptible to developing RA than second-degree relatives
31 (Q3). Interestingly, some felt that they were more susceptible to developing RA than other
32 first-degree relatives because they appeared to follow other patterns of illness displayed by
33 their relative with RA (Q4). Additional biological factors, such as being female and some
34 environmental factors were also described as playing a role in the development of RA
35 (Q2&5).
36
37
38
39
40
41
42
43
44

45 When considering their perceived personal susceptibility, relatives reported that there were
46 aspects of familial risk, particularly genetic susceptibility, which they found difficult to
47 understand. One relative felt that effectively communicating an understanding of genetic
48 risk to the public was extremely challenging (Q6). Others felt that they needed more
49 information about their level of risk as a relative and the specific role that genes associated
50 with RA played in this risk (Q7).
51
52
53
54
55
56
57
58
59
60

1
2
3 When considering their susceptibility to RA, relatives voiced their concerns about the future,
4 and how being at risk of developing RA was a worry for them. Those who had considered
5 their personal susceptibility to RA, described being fearful of what they may uncover if they
6 were to have their risk quantified. For some, the prospect of living with RA would entail
7 great amounts of uncertainty (Q8). For many, having witnessed the impact of RA on their
8 sibling / parent, heightened the worry they felt in relation to the possibility of developing RA
9 themselves in the future (Q9). Interestingly, a small number of relatives had experienced
10 joint related symptoms but had not yet sought medical advice, being fearful of the potential
11 outcome (Q10).
12
13
14
15
16
17
18
19
20
21

22 **Personal considerations of RA risk and communication about risk within families**

23
24 Relatives discussed knowing little about RA or its risk factors, feeling that they had been
25 “shielded” or “protected” from this knowledge by their sibling / parent (Q11). Also, relatives
26 described how they rarely discussed RA within their family unit, and in some cases the
27 invitation to participate in this study was the first time that the opportunity to discuss RA,
28 and its risk had emerged (Q12). For one relative, receiving the invitation to take part in this
29 study facilitated the first conversation he had had with his father about RA (Q13). Another
30 described how his mother had had some concerns about him taking part in this study,
31 because of the worry which discussing issues surrounding risk and predictive testing may
32 cause (Q14). One relative described how her brother had been asked to take part in this
33 study, but ignored the request; her mother had then approached her and encouraged her to
34 participate (Q15). This relative suggested that it was her attitude towards health which set
35 her apart from her brother.
36
37
38
39
40
41
42
43
44
45

46 Most relatives had not fully considered issues related to their personal susceptibility to RA
47 prior to being approached to take part in this study (Q16). Some relatives indicated that
48 taking part in this study had been a positive experience for them and had provided them
49 with much needed knowledge, a chance for reflection on their risk and a greater
50 understanding of RA and how it affected their sibling / parent (Q17). However, others
51 described how they would prefer to avoid considering their personal risk of RA to avoid
52 experiencing worry or anxiety about the future (Q18).
53
54
55
56
57
58
59
60

Perceptions surrounding the use of predictive tests: positive perspectives

Most relatives were in favour of the basic principle behind predictive testing - identifying those at risk and quantifying the level of risk (Q19). It was also felt that the information gained from predictive testing could be acted upon to reduce the future risk of developing RA (Q20). In particular, relatives recognised the importance of early intervention, and were aware that testing could put them “on alert” for the early symptoms of RA (Q21), or suggested that they might be able to take preventive treatment (Q22). Many relatives felt that it was important to know that they were at risk, and that information related to their actual risk would be of value to them, allowing them to “mentally” prepare for the future (Q23). Others could see the benefit of preparing for the functional limitations that may be associated with RA (Q24). A few had already undertaken predictive testing to explore their personal risk of developing RA (Q25). Some were willing to be tested for altruistic reasons such as taking part in research (Q26).

Perceptions surrounding the use of predictive tests: negative perspectives

The ability of predictive tests to quantify risk was widely discussed (Q27), with one participant questioning the specificity and sensitivity of the test (Q28). Relatives expressed a desire for tests that would, with a very high likelihood, be able to confirm or exclude the fact that they would develop RA (Q29). However, many relatives suspected that test results would give them an intermediate risk of developing RA and others highlighted concerns about “false positive” results (Q30). Some believed that predictive testing would not be able to give them answers to questions they thought were important for example how severe would their RA be were they to develop it, and when it would be most likely to begin (Q31).

Relatives were worried about the impact of testing on their family members and in particular on their sibling / parent with RA (Q32). Participants felt that by seeking information about risk and pursuing testing that they would cause their relative with RA to experience stress, worry or feelings of guilt. Participants were further worried about the stress that predictive test results may cause them. One even suggested that such stress could cause the disease to develop earlier than it otherwise would (Q33).

1
2
3
4
5
6 Relatives felt that being given risk information when they were young would be a particular
7 burden (Q34). Instead, they felt that testing should be left until later in life, when the
8 chance of developing a condition like RA was higher. Risk information was considered to
9 have significant implications for future life choices and could make them “rush” though life
10 (Q35). One relative suggested such information could bring forward major life decisions, such
11 as having children (Q36).
12
13
14
15
16

17
18 Some relatives reflected upon previous negative personal experiences of having received
19 poorly communicated test related information (Q37). For some, the approach to the
20 delivery of risk information represented an important feature of a predictive test, and may
21 determine whether the test would be acceptable to them. Relatives discussed how they
22 would want to be told prior to the test what format the result would take. Some suggested
23 that they would like to receive the results by letter, and then be given the opportunity to
24 discuss the results with a healthcare professional (Q38). Other relatives emphasized the
25 importance of talking to someone about the test result, especially to manage the
26 psychological distress that may be associated with receiving a “positive” test result (Q39).
27 Many relatives felt that there was a need for ongoing support from a healthcare
28 professional following testing (Q40).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

This study explored the degree to which first-degree relatives of people with RA felt that they were susceptible to developing RA and their perceptions of predictive testing. Most relatives were aware that there was a genetic contribution to the risk of RA, and that they may be susceptible to developing RA; however they were unsure of the extent of the additional risk. Relatives highlighted the need for additional information about familial risk and described the need for better communication strategies in relation to imparting this information.

Generally, first-degree relatives felt that there was a need for more information and support specifically designed for the family members of people with RA. The current lack of support and information was suggested to have a number of effects, including family members not feeling able to communicate and support the person affected with RA and not feeling able to understand concepts surrounding the nature of RA and the risks associated with RA. Studies of information sharing amongst family members at risk of cancer have found that patients with the disease do not always communicate risk information in a timely or thorough fashion.⁴² Forrest et al found that relatives from smaller families, and female relatives were more likely to make contact with genetic services.⁴³ Research has shown that genetic counselling can facilitate interfamily communication, and can help to minimize distress and increase the number of family members making contact with health services to be tested.^{44;45}

An incidental finding of this research was that being invited to take part in research about risk was the first time that some relatives had fully considered their personal susceptibility to RA. In some cases this exposure was viewed positively but in other cases it caused worry and concern. It is difficult to draw conclusions about the specific impact taking part in this study had on relatives' well-being but we note that relatives did indicate that support mechanisms would be helpful to enable them to understand and cope with risk related information, especially if predictive testing were to be offered. We would suggest that

1
2
3 researchers accessing participants in “at risk” populations pay particular attention to the
4 impact that an invitation to participate and participation itself may have, and offer
5 additional support to mitigate against anxiety caused. While personal susceptibility may not
6 have been considered, perceptions of RA severity may predict personal willingness to
7 engage in predictive testing. It is possible that first degree relatives of people with more
8 severe forms of RA or poorly controlled disease maybe more motivated to engage in
9 predictive testing. This would be in line with the predictions of the health belief model.⁴⁶ A
10 quantitative investigation to assess the effect of factors such as disease severity in people
11 with RA, on their family members’ perceptions of risk and orientation towards predictive
12 testing is needed to test this hypothesis.
13
14
15
16
17
18
19
20
21

22 In addition, it became apparent during the course of this study that some relatives were
23 symptomatic but had not yet sought medical help. Detailed information on the health status
24 of the participating relatives was not gathered within this study but those who were
25 symptomatic were advised to speak to their family physician, and were given details of
26 resources for obtaining additional information. However, the symptomatic nature of some
27 relatives raises important issues surrounding informing relatives about risk, and the
28 importance of seeking help quickly should symptoms emerge. While some relatives were
29 aware that their symptoms may be indicative of the early stages of RA, and were worried
30 about what information would be revealed to them if they sought help, few were aware of
31 the importance of early intervention. Were information about the benefits of early
32 intervention in preventing joint destruction made available to them, it is possible that their
33 attitude to help seeking may have been different.
34
35
36
37
38
39
40
41
42
43
44

45 This study has a number of limitations. Firstly, our access to first-degree relatives was via
46 patients with RA. Some relatives described how they were chosen in preference to other
47 relatives, who would either worry too much or not be receptive to discussing issues related
48 to risk. The findings presented here may thus not fully reflect the range of views related to
49 risk and testing held by first-degree relatives. This potential limitation highlights the need to
50 fully understand the barriers that patients with RA face when discussing issues of risk with
51 family members. A second limitation of this research was that the majority of participants
52 were female. A criticism of many qualitative studies in the field of RA is that the male
53
54
55
56
57
58
59
60

1
2
3 perspective is underrepresented.⁸ While the female: male ratio of RA is typically 2:1 it is
4 essential that studies attempt to include the views of more male participants. Therefore, we
5 acknowledge that themes related to gender and male perspectives of risk and predictive
6 testing did not reach saturation and are not represented in our data. A final limitation is that
7 only a small number of individuals from ethnic-minority communities were interviewed,
8 therefore, a full understanding of the cultural barriers to predictive testing was not
9 achieved.
10
11
12
13
14

15
16
17 Besides these limitations, this study has a number of strengths. Relatives were sampled
18 from centres in 3 different European countries and saturation of the main themes was
19 achieved by combining interview data from all centres; furthermore, no differences in the
20 views expressed by relatives sampled from different European countries were detected.
21 Gathering data from multiple countries means that interventions developed based on these
22 data are likely to be relevant in multiple contexts. A further strength of this study was the
23 support given by an international panel of patient research partners who advised
24 researchers and acted as co-researchers.
25
26
27
28
29
30
31
32

33 Identifying individuals at risk of RA may allow targeted interventions to reduce the risk and
34 consequence of future disease; however, our data show that relatives have concerns about
35 predictive testing and risk information that would result from it (the key messages of this
36 study are summarised in table 7). The future development of strategies to quantify and
37 communicate risk needs to take these views into account and incorporate approaches to
38 mitigate concerns and minimize any negative psychological impact of risk information.
39
40
41
42
43
44

45 **Data Sharing Statement**

46 Unpublished data is available in the form of unanalysed interview transcripts sorted in an
47 NVIVO file from the corresponding author. Data can be obtained by emailing the
48 corresponding author.
49
50
51
52
53
54
55
56
57
58
59
60

Reference List

- (1) Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. *Rheumatology (Oxford)* 2002; 41(7):793-800.
- (2) Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. *Arthritis Rheum* 1998; 41(5):778-799.
- (3) Stack RJ, Shani M, Mallen CD, Raza K. Symptom complexes at the earliest phases of rheumatoid arthritis: a synthesis of the qualitative literature. *Arthritis Care Res* 2013; 65(12):1916-1926.
- (4) Stack RJ, van Tuyl LH, Sloots M, van de Stadt LA, Hoogland W, Matt B et al. Symptom complexes in patients with seropositive arthralgia and in patients newly diagnosed with rheumatoid arthritis: A qualitative exploration of symptom development. *Rheumatology (Oxford)* 2014; 53(9):1646-1653.
- (5) Chan KWA, Felson DT, Yood RA, Walker AM. The Lag Time Between Onset of Symptoms and Diagnosis (Dx) of Rheumatoid-Arthritis (Ra) and Its Determinants. *Arthritis and Rheumatism* 1992; 35(9):S125.
- (6) Kiely P, Williams R, Walsh D, Young A. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. *Rheumatology (Oxford)* 2009; 48(1):57-60.
- (7) Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. *Rheumatology (Oxford)* 2004; 43(7):906-914.
- (8) Stack RJ, Shaw K, Mallen C, Herron-Marx S, Horne R, Raza K. Delays in help seeking at the onset of the symptoms of rheumatoid arthritis: a systematic synthesis of qualitative literature. *Ann Rheum Dis* 2012; 71(4):493-497.
- (9) Gerlag DM, Raza K, van Baarsen LG, Brouwer E, Buckley CD, Burmester GR et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. *Ann Rheum Dis* 2012; 71(5):638-641.
- (10) Karlson EW, van SD, van der Helm-van Mil AH. Strategies to predict rheumatoid arthritis development in at-risk populations. *Rheumatology (Oxford)* 2014.
- (11) Raza K, Filer A. Predicting the development of RA in patients with early undifferentiated arthritis. *Best Pract Res Clin Rheumatol* 2009; 23(1):25-36.
- (12) Yarwood A, Huizinga TW, Worthington J. The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. *Rheumatology (Oxford)* 2014.

- 1
2
3 (13) MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K et al.
4 Characterizing the quantitative genetic contribution to rheumatoid arthritis using data
5 from twins. *Arthritis Rheum* 2000; 43(1):30-37.
6
7 (14) Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K et al. Genetics of rheumatoid
8 arthritis contributes to biology and drug discovery. *Nature* 2014; 506(7488):376-381.
9
10 (15) Kim K, Bang SY, Lee HS, Cho SK, Choi CB, Sung YK et al. High-density
11 genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid
12 arthritis risk loci. *Ann Rheum Dis* 2015; 74(3):e13.
13
14 (16) Somers EC, Antonsen S, Pedersen L, Sorensen HT. Parental history of lupus and
15 rheumatoid arthritis and risk in offspring in a nationwide cohort study: does sex
16 matter? *Ann Rheum Dis* 2013; 72(4):525-529.
17
18 (17) Grant SF, Thorleifsson G, Frigge ML, Thorsteinsson J, Gunnlaugsdottir B, Geirsson
19 AJ et al. The inheritance of rheumatoid arthritis in Iceland. *Arthritis Rheum* 2001;
20 44(10):2247-2254.
21
22 (18) Frisell T, Holmqvist M, Kallberg H, Klareskog L, Alfredsson L, Askling J. Familial
23 risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-
24 citrullinated protein antibody status, number and type of affected relatives, sex, and
25 age. *Arthritis Rheum* 2013; 65(11):2773-2782.
26
27 (19) Too CL, Muhamad NA, Ilar A, Padyukov L, Alfredsson L, Klareskog L et al.
28 Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results
29 from a Malaysian population-based case-control study. *Ann Rheum Dis* 2015.
30
31 (20) Qin B, Yang M, Fu H, Ma N, Wei T, Tang Q et al. Body mass index and the risk of
32 rheumatoid arthritis: a systematic review and dose-response meta-analysis. *Arthritis
33 Res Ther* 2015; 17:86.
34
35 (21) Chou YY, Lai KL, Chen DY, Lin CH, Chen HH. Rheumatoid Arthritis Risk
36 Associated with Periodontitis Exposure: A Nationwide, Population-Based Cohort
37 Study. *PLoS One* 2015; 10(10):e0139693.
38
39 (22) Orellana C, Saevarsdottir S, Klareskog L, Karlson EW, Alfredsson L, Bengtsson C.
40 Postmenopausal hormone therapy and the risk of rheumatoid arthritis: results from the
41 Swedish EIRA population-based case-control study. *Eur J Epidemiol* 2015;
42 30(5):449-457.
43
44 (23) Stoll T, Gordon C, Seifert B, Richardson K, Malik J, Bacon PA et al. Consistency and
45 validity of patient administered assessment of quality of life by the MOS SF-36; its
46 association with disease activity and damage in patients with systemic lupus
47 erythematosus. *J Rheumatol* 1997; 24(8):1608-1614.
48
49 (24) Pattison DJ, Silman AJ, Goodson NJ, Lunt M, Bunn D, Luben R et al. Vitamin C and
50 the risk of developing inflammatory polyarthritis: prospective nested case-control
51 study. *Ann Rheum Dis* 2004; 63(7):843-847.
52
53
54
55
56
57
58
59
60

- 1
2
3 (25) Pattison DJ, Symmons DP, Lunt M, Welch A, Luben R, Bingham SA et al. Dietary
4 risk factors for the development of inflammatory polyarthritis: evidence for a role of
5 high level of red meat consumption. *Arthritis Rheum* 2004; 50(12):3804-3812.
6
7 (26) Rosell M, Wesley AM, Rydin K, Klareskog L, Alfredsson L. Dietary fish and fish oil
8 and the risk of rheumatoid arthritis. *Epidemiology* 2009; 20(6):896-901.
9
10 (27) Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J et al. A
11 new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR
12 (shared epitope)-restricted immune reactions to autoantigens modified by
13 citrullination. *Arthritis Rheum* 2006; 54(1):38-46.
14
15 (28) Sparks JA, Chang SC, Liao KP, Lu B, Fine AR, Solomon DH et al. Rheumatoid
16 arthritis and mortality among women during 36 years of prospective follow-up:
17 Results from the Nurses' Health Study. *Arthritis Care Res (Hoboken)* 2015.
18
19 (29) Sparks JA, Chen CY, Jiang X, Askling J, Hiraki LT, Malspeis S et al. Improved
20 performance of epidemiologic and genetic risk models for rheumatoid arthritis
21 serologic phenotypes using family history. *Ann Rheum Dis* 2015; 74(8):1522-1529.
22
23 (30) Aho K, Palosuo T, Raunio V, Puska P, Aromaa A, Salonen JT. When does
24 rheumatoid disease start? *Arthritis Rheum* 1985; 28(5):485-489.
25
26 (31) Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et
27 al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict
28 the development of rheumatoid arthritis. *Arthritis Rheum* 2003; 48(10):2741-2749.
29
30 (32) Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van SD et al. Anti-
31 carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis.
32 *Ann Rheum Dis* 2014; 73(4):780-783.
33
34 (33) de Hair MJ, van de Sande MG, Ramwadhoebe TH, Hansson M, Landewe R, van der
35 Leij C et al. Features of the synovium of individuals at risk of developing rheumatoid
36 arthritis: implications for understanding preclinical rheumatoid arthritis. *Arthritis*
37 *Rheumatol* 2014; 66(3):513-522.
38
39 (34) Gent YY, Voskuyl AE, Kloet RW, van SD, Hoekstra OS, Dijkmans BA et al.
40 Macrophage positron emission tomography imaging as a biomarker for preclinical
41 rheumatoid arthritis: findings of a prospective pilot study. *Arthritis Rheum* 2012;
42 64(1):62-66.
43
44 (35) Ferucci ED, Darrach E, Smolik I, Choromanski TL, Robinson DB, Newkirk MM et al.
45 Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid
46 arthritis and unaffected first-degree relatives in indigenous North American
47 Populations. *J Rheumatol* 2013; 40(9):1523-1528.
48
49 (36) Sparks JA, Iversen MD, Kroouze RM, Mahmoud TG, Triedman NA, Kalia SS et al.
50 Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study:
51 Rationale and design for a randomized controlled trial evaluating rheumatoid arthritis
52 risk education to first-degree relatives. *Contemporary Clinical Trials* 2014;
53 39(1):145-157.
54
55
56
57
58
59
60

- 1
2
3 (37) Novotny F, Haeny S, Hudelson P, Escher M, Finckh A. Primary prevention of
4 rheumatoid arthritis: a qualitative study in a high-risk population. *Joint Bone Spine*
5 2013; 80(6):673-674.
6
7 (38) Bayliss K, Raza K, Simons G, Falahee M, Hansson M, Starling B et al. Perceptions of
8 predictive testing for those at risk of developing a chronic inflammatory disease: a
9 meta-synthesis of qualitative studies. *Journal of Risk Research*. In press 2016.
10
11 (39) Falahee M, Simons G, Raza K, Stack RJ. Healthcare professionals' perceptions of risk
12 in the context of genetic testing for the prediction of chronic disease: A qualitative
13 metasynthesis. *Journal of Risk Research*. In press 2016.
14
15 (40) Guest GS, MacQueen KM, Namey EE. *Applied Thematic Analysis*. Thousand Oaks,
16 California: Sage Publications; 2012.
17
18 (41) NVivo qualitative data analysis software; QSR International Pty Ltd. Version 8 [
19 2008].
20
21 (42) Forrest LE, Curnow L, Delatycki MB, Skene L, Aitken M. Health first, genetics
22 second: exploring families' experiences of communicating genetic information. *Eur J*
23 *Hum Genet* 2008; 16(11):1329-1335.
24
25 (43) Forrest L, Delatycki M, Curnow L, Gen CM, Skene L, Aitken M. An audit of clinical
26 service examining the uptake of genetic testing by at-risk family members. *Genet Med*
27 2012; 14(1):122-128.
28
29 (44) Forrest LE, Burke J, Bacic S, Amor DJ. Increased genetic counseling support
30 improves communication of genetic information in families. *Genet Med* 2008;
31 10(3):167-172.
32
33 (45) Forrest LE, Delatycki MB, Skene L, Aitken M. Communicating genetic information
34 in families--a review of guidelines and position papers. *Eur J Hum Genet* 2007;
35 15(6):612-618.
36
37 (46) Rollins BL, Ramakrishnan S, Perri M. Direct-to-consumer advertising of predictive
38 genetic tests: a health belief model based examination of consumer response. *Health*
39 *Mark Q* 2014; 31(3):263-278.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Sample interview schedule for those at risk of developing RA

- Tell me what you know about RA?

PROMPTS: What do you think the causes of RA could be? What do you think the risks factors for RA are? Tell me about how serious you think RA is? How would you know you had RA e.g what symptoms would you expect? What would be the impact of RA on your life? Do you think you would be able to control RA yourself? Do you think there are treatments available that would effectively treat RA?

- Do you ever worry about the possibility of developing RA in the future?
- What would you think if you were told that you could have a test that would tell you how likely you were to develop RA?

PROMPTS: What sort of information should this test give you? When do you think would be the right time to get this information? How would you feel about the idea of having a test that would tell you your chance of developing RA in the future? In what ways do you think it would be helpful for you to know your chances of developing RA?

- What would your concerns be if you knew what your risk of developing RA was?
- What kind of tests do you think people might be able to do to work out whether or not you might develop RA (test that are available now and tests that might become available in the future)?

Table 2: Details of first degree relatives of RA patients who participated in the interviews

Participant no.	Gender	Age	Ethnicity	Relation to RA patient	Experience of testing	Self-reported musculoskeletal symptoms	Interview country
Participant 1	Female	36	White British	Daughter	None	None	UK
Participant 2	Female	42	White British	Daughter	None	Previous septic arthritis	UK
Participant 3	Male	35	White British	Son	None	None	UK
Participant 4	Male	67	White British	Brother	None	None	UK
Participant 5	Male	31	White British	Son	Reports having had a “genetic test” for RA (performed by family physician).	None	UK
Participant 6	Female	23	White British	Daughter	None	None	UK
Participant 7	Female	30	White British	Daughter	None	Ankle pain and intermittent ankle swelling attributed by patient to a previous “ankle dislocation”	UK
Participant 8	Female	39	White British	Daughter	Rheumatoid factor	Elbow pain	UK

previously

measured

Participant 9	Female	54	White British	Sister	None	Finger pain	UK
--------------------------------	--------	----	------------------	--------	------	-------------	----

Participant 10	Female	35	White British	Daughter	None	“Inflamed knee” during pregnancy	UK
---------------------------------	--------	----	------------------	----------	------	--	----

Participant 11	Female	44	White British	Sister AND Daughter	None	Back pain	UK
---------------------------------	--------	----	------------------	---------------------------	------	-----------	----

Participant 12	Female	44	White British	Sister	None	Finger pain	UK
---------------------------------	--------	----	------------------	--------	------	-------------	----

Participant 13	Female	41	White British	Sister AND Daughter	Rheumatoid factor previously measured by family physician	Finger pain, stiffness and swelling	UK
---------------------------------	--------	----	------------------	---------------------------	--	---	----

Participant 14	Female	60	White	Daughter	Has had “blood tests” (participant unsure which)	Has a diagnosis of osteoarthritis	UK
---------------------------------	--------	----	-------	----------	---	--------------------------------------	----

Participant 15	Female	29	White British	Daughter	None	None	UK
---------------------------------	--------	----	------------------	----------	------	------	----

Participant 16	Female	40	White British	Daughter	None	None	UK
Participant 17	Female	41	Asian (UK born)	Daughter	None	None	UK
Participant 18	Female	28	White British	Daughter	None	None	UK
Participant 19	Male	42	Chinese	Son	None	None	UK
Participant 20	Female	25	White British	Daughter	None	None	UK
Participant 21	Female	41	White British	Daughter	None	Had previous joint swelling in wrists and hands	UK
Participant 22	Female	32	White British	Sister	None	None	UK
Participant 23	Female	44	White British	Daughter	None	None	UK
Participant 24	Male	47	White British	Son	None	None	UK
Participant 25	Female	29	White German	Daughter	None	None	Germany

Participant	Female	37	White	Daughter	None	None	Germany
26			German				
Participant	Female	51	White	Daughter	None	None	Germany
27			German				
Participant	Female	21	White	Daughter	None	None	Austria
28			Austrian				
Participant	Male	33	White	Son	None	None	Austria
29			Austrian				
Participant	Female	65	White	Sister	None	None	Austria
30			Austrian				
Participant	Female	36	White	Sister	Reports	None	Austria
31			Austrian		having had		
					a blood test		
Participant	Male	37	White	Son	None	None	Austria
32			Austrian				
Participant	Male	37	White	Son	None	None	Austria
33			Austrian				
Participant	Female	33	White	Daughter	None	None	Austria
34			Austrian				

Table 3 Quotations related to an understanding of family history and genetic factors as risk factors for rheumatoid arthritis

Code	Quotation
Q1	<i>"I see that my mother has it and I'm just worried that it might be passed on to me or my sister or other members of my family." (Participant 19)</i>
Q2	<i>"In my opinion it's environmental factors or genetics." (Participant 28)</i>
Q3	<i>"So I know it's blood-related... I think if it was your cousin or your aunt there'd be a slim chance..... being direct blood-related, I would class myself as, or think of myself that I am at a higher risk than most." (Participant 6)</i>
Q4	<i>"I seem to follow my mum in absolutely everything, like my brother and sister they're quite like my dad, they never get ill, they never catch a cold. Whereas if there's a cold going around I will get it and the same with my mum... So I was a bit like 'oh, maybe I'll get it'." (Participant 18)</i>
Q5	<i>"I know that there's a genetic tendency. That it runs in families. I'm female, so I'm more at risk because I'm female... I know first degree relative increases your risk, so yeah, it does worry me." (Participant 10)</i>
Q6	<i>"Genetics really worry me because I don't know anything about them and I think when people think of genetics they think of like I don't know it's quite like a complicated thing that we're never going to understand because there's no simple way of putting it.... But like your average Joe Bloggs [average person] isn't going to know extensive information about your genes." (Participant 20)</i>
Q7	<i>"For me personally it's kind of hard facts and figures; I'm more comfortable knowing in terms of percentages. I know my dad has got rheumatoid arthritis, and if you've got a hard fact and figure to say that the chances of a close relative, son or daughter, developing rheumatoid arthritis at some point in their life then that information would be useful to me." (Participant 5)</i>
Q8	<i>"It [life] wouldn't be predictable anymore; I wouldn't know how things would be from one day to the next, or in an hour's time, when I woke up the next morning, wondering what the day would bring. I think it's pretty serious, it restricts your everyday life. And it differs – my father has pain and sometimes it's there,</i>

	<i>sometimes it's not; it's unpredictable." (Participant 25)</i>
Q9	<i>"I do worry about it, yeah, because I don't want to end up developing anything like that. I like to keep busy and I don't want to be restricted. It is a big worry, yeah. I don't want to go through what my mum's going through at the moment, because she's been through a lot." (Participant 13)</i>
Q10	<i>"I've got pain down my left leg [okay], but I just don't know whether it's sciatica, or whether it could be something linked to arthritis, but I'm too frightened to go and have a scan. So I probably do need it to find that. I'm just putting it off." (Participant 15)</i>

Table 4 Quotation related to personal considerations of rheumatoid arthritis risk and communication about risk within families

Code	Quotation
Q11	<i>"That's exactly what he doesn't talk to me about, he's the kind of person who leaves others out of it, deals with it by himself." (Participant 30)</i>
Q12	<i>"I am worried about that...I was quite surprised when mum said that she'd had this letter explaining about the research that you're doing." (Participant 23)</i>
Q13	<i>"He doesn't tend to talk about it. He didn't want to ask me to do this phone call, but forced himself to one day...This is probably the first time he's actually asked me to do anything and he was clearly uncomfortable." (Participant 24)</i>
Q14	<i>"I never had that information of what happens, how you're made at higher risk, I've never had that in like black and whitewhich makes me think she doesn't know or maybe she's just trying to protect me like a mother does. Because I think she was quite worried about me taking part....she's quite worried about what I'd find out. (Participant 5)</i>
Q15	<i>"My mum, sort of, mentioned this to him [brother], and he was just, like, ignored the fact that she'd said anything to me. And then she came to me and said, 'I thought I'd ask your brother first but he won't,' and I said, 'I don't mind,' but he's probably different to me, just blissful ignorance, whereas I'm probably a little bit different." (Participant 2)</i>
Q16	<i>"Up until now I have never thought about it, what that would be like, whether it might happen" (Participant 28)</i>
Q17	<i>"I guess before we spoke I couldn't understand what it was exactly that was making her finger sore or swollen or anything like that. I would just be like, drink more milk." (Participant 20)</i>
Q18	<i>"You only worry too much and rack your brain, because then I have to consider that my children could get it too and then you would worry too much. It's more comfortable to avoid it." (Participant 32,)</i>

Table 5 Quotations related to perceptions surrounding the use of predictive tests: positive perspectives

Code	Quotation
Q19	<i>"I'm open to everything, well, I don't know why I shouldn't have that done, I couldn't think of a reason off the top of my head not to do it." (Participant 31)</i>
Q20	<i>"If I was offered a test, I'd be very happy to have one. I don't need to think about that. Well, it might be if it might help me combat a disease later, or at least know how to treat it. Well, if I'm at risk I think it would be helpful to know." (Participant 3)</i>
Q21	<i>"I would do that straight away, because I want to know as soon as possible, because I think the more you know the earlier, the more you can do about it." (Participant 31)</i>
Q22	<i>"I think that with kind of information, I'd be more keen to, sort of, sort out what I needed to do to try and prevent that becoming a problem. If I could take some sort of medication to...head it off before it became a big problem." (Participant 2)</i>
Q23	<i>"I think that would be a good thing. I think I'd like to know because then I may be able to prepare a bit more, like mentally as well." (Participant 20)</i>
Q24	<i>"Yes, it would. I think I would have the test just to see what the long-term forecast is, because my job's fairly labour intensive. I'd be willing to know what the future holds, just from the point of view of my job circumstances at work." (Participant 19)</i>
Q25	<i>"Actually I did get tested, but it was a long time ago." (Participant 27)</i>
Q26	<i>"I'm not averse to having them, especially, if it helps with research and stuff like that." (Participant 2)</i>

**Table 6 Quotations related to perceptions surrounding the use of predictive tests:
negative perspectives**

Code	Quotation
Q27	<i>"Exactly, if it is only a vague presumption where they say, yes, you could perhaps out of two to five people or something, you could get it and the others wouldn't, well that is very vague. (Participant 32)</i>
Q28	<i>"That depends on the test, how specified it is and how sensitive it is, otherwise I would not have the test done." (Participant 29)</i>
Q29	<i>"Because if told me – it's only how likely, it's not a, 'You will develop it,' and it doesn't tell you when you will develop it. So I think if somebody said to me, 'There's this test out there and it'll tell you whether you might develop it,' I wouldn't want it, because you could just live your life in fear and never actually develop it. So unless it was 100% guaranteed, and somebody could say, 'You will develop it within this time frame,' I don't wanna [want to] spend the next 30 years worrying about something, when I could be enjoying those 30 years. So, no, I'd probably – it depends on the exact details of the test. (Participant 10)</i>
Q30	<i>"Or, equally, I guess, false positive. If you've got one really bad, sort of, joint that you've tested, it could, kind of, put a bit of a negative spin on it." (Participant 1)</i>
Q31	<i>"It would be nice to know when ... at what point in time you were going to get ill, and how severe it was going to be ... but I don't know whether a test can find that out. (Participant 25)</i>
Q32	<i>"But I wouldn't want to worry my mum by saying, can you get me a leaflet on testing. I wouldn't want my mum to worry that I was going for this test....to know that if in five years time I'll get it, I don't want her to know that because I think that would worry her more than anything." (Participant 6)</i>
Q33	<i>"On the one hand you know that you might develop the disease and it is of course stressful, because then you know, one day, when I'm about 30 – 40 years old, it will start and then my body will become weaker and I will get this disease, then it could create a lot of stress to have these negative thoughts. I don't know what the psychological effect would be on the body, whether it really might break out</i>

	<i>sooner. If you don't know, so, if you say, I don't know and you live each day as it comes, meaning that it might break out at a later date." (Participant 32)</i>
Q34	<i>"From personal experience, I think it would be something that when I got a bit older and certain things started going wrong with me or I started getting more illnesses I'd think I'd need to start looking to what all these problems are. At this particular moment in time, when there's generally nothing wrong with me, I just think that I don't really need to delve too much into that sort of information."(Participant 4)</i>
Q35	<i>"Yeah I kind of wouldn't want this test to tell me that I had a 50/50 chance of getting it in the next five years because that would change my entire perception on what I wanted. And I guess if someone gave me that bit of information I'd have to seriously think, well maybe I can't have that, maybe I've got to like push everything forward like get married and have kids before I start to take medication which I guess that's a lot of information I don't know about in that if I had to start taking that medication would that affect me having kids. It's like knowing when you're going to die that doesn't sit right with me either." (Participant 15)</i>
Q36	<i>"I think, if, for argument's sake, I'd gone for the test tomorrow, and the results came back and they said, 'Yeah, you're at high risk,' and in two years' time, the symptoms kicked in, you're then thinking, 'Right, okay.' We'd probably want a second child and we'd want a third, 'Let's do it now,' sort of, thing, but otherwise, I think, you know, just life would carry on" (Participant 6,)</i>
Q37	<i>"The GP [family physician] literally just sat me down, blurted some technical words out, medical terminology to me that went straight over my head and, again, didn't sink. I think, just keep simple, instead of baffling people with medical science, really, of your technical words that you use, compared to what, sort of, the general public are going to understand." (Participant 6)</i>
Q38	<i>"I'd be happy, I think, if, before the test, someone would explain the kind of outcome to expect. And then when I got the test results back, it would be okay by post, as long as there was, kind of, accompanying information. I suppose at that point you'd probably end up going to see someone anyway to talk through what tablets or whatever you could take." (Participant 1)</i>

Q39	<i>"I suppose it would be sensible to go and talk to somebody about it. (Participant 3)</i>
Q40	<i>"I think it's a good idea to talk to somebody and find out more information. I think seeing somebody on a regular basis, like every year or something, might be good if you knew that you were going to get it. Obviously, you're going to have more and more questions, aren't you? Yeah, for an update and just to see how things are going. Obviously, as time goes on, you're going to have more questions and so I think it would be good to speak to somebody." (Participant 20)</i>

Table 7: Key messages

1. Identifying those at risk of RA, and quantifying their risk, may help guide targeted interventions to reduce future disease burden. This qualitative study found that first-degree relatives of people with RA, who are themselves at an enhanced risk of RA, had a number of concerns in relation to predictive testing.
2. Some relatives would be unwilling to undergo predictive testing and were worried about the psychological impact of risk information. Others were more receptive and recognized that such information could facilitate the development and implementation of preventive strategies as well as encouraging prompt help-seeking and intervention at the onset of RA symptoms.
3. Developing strategies which communicate risk information effectively while reducing the psychological burden associated with this information is essential.

1
2
3 **Title: Perceptions of risk and predictive testing held by the first degree relatives of**
4 **patients with rheumatoid arthritis in England, Austria and Germany: a qualitative study**
5
6
7

8 **Authors**
9

10 Rebecca J Stack^{1,2}, Michaela Stoffer^{3,4}, Mathias Englbrecht⁵, Erika Mosor,³ Marie Falahee¹,
11 Gwenda Simons¹, Josef Smolen³, Georg Schett⁵, Chris D Buckley^{1,2}, Kanta Kumar⁶, Mats
12 Hansson⁷, Axel Hueber⁵, Tanja Stamm³, Karim Raza^{1,8}
13
14
15

16
17 **Affiliations**
18

- 19 1. Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University
20 of Birmingham, UK
21
22 2. Division of Psychology, Nottingham Trent University, Nottingham, UK
23
24 3. Division of Rheumatology, Department of Internal Medicine III Medical University of
25 Vienna, Austria
26
27 4. University of Applied Sciences for Health Professionals, Upper Austria, Austria
28
29 5. Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen,
30 Germany
31
32 6. School of Nursing, Faculty of Medical and Human Sciences, University of Manchester, UK
33
34 7. Centre for Research Ethics and Bioethics, Uppsala University, Sweden
35
36 8. Department of Rheumatology, Sandwell & West Birmingham Hospitals NHS Trust,
37 Birmingham, UK
38
39
40
41
42

43 **Correspondence to:**

44 Dr. Rebecca J Stack, Division of Psychology, School of Social Sciences, Nottingham Trent
45 University, NG14BU, UK rebecca.stack@ntu.ac.uk
46
47
48

49 **Keywords**
50

51 Risk, Rheumatoid Arthritis, First-degree Relatives, Predictive testing, Qualitative
52
53
54
55
56
57
58
59
60

Abstract

Objectives: The family members of rheumatoid arthritis (RA) patients are at increased risk of developing RA and are potential candidates for predictive testing. This study explored the perceptions of first degree relatives of people with RA about being at risk of RA and engaging in predictive testing.

Methods: Thirty-four first-degree relatives (siblings and off-spring) of patients with RA from the UK, Germany and Austria participated in semi-structured interviews about their perceptions of RA risk and the prospect of predictive testing. Interviews were audio-recorded, transcribed verbatim and analysed using thematic analysis.

Results: First-degree relatives were aware of their susceptibility to RA, but were unsure of the extent of their risk. When considering their future risk, some relatives were concerned about the potential impact that RA would have on their lives. Relatives were concerned that knowing their actual risk would increase their anxiety and would impact decisions about their future. Also, relatives were concerned about the levels of uncertainty associated with predictive testing. Those in favour of knowing their future risk felt that they would need additional support to understand the risk information and cope with the emotional impact of this information.

Conclusions: Identifying individuals at risk of RA may allow targeted interventions to reduce the risk and consequence of future disease; however, relatives have concerns about predictive testing and risk information. The development of strategies to quantify and communicate risk needs to take these views into account and incorporate approaches to mitigate concerns and minimize the psychological impact of risk information.

Strengths and limitations

- This study used inductive qualitative interviews to explore perceptions about risk and predictive testing in the first-degree relatives of people with RA.
- This study identified positive and negative perspectives surrounding predictive testing, and why some people at risk may not wish to be tested.

- Further research is needed to quantify the numbers of people at risk holding negative perceptions about predictive testing, and identify the behavioural implications of these beliefs.
- Communicating risk information to relatives effectively while reducing the psychological burden associated with this information, should be the focus of future interventional research.

For peer review only

Funding statement

This work was supported by European Union by within the FP7 HEALTH programme under the grant agreement FP7-HEALTH-F2-2012-305549 (EuroTEAM) and by Riksbankens Jubileumsfond (The Swedish Foundation for Humanities and Social Sciences) under Grant M13-0260:1 'Mind the Risk'.

Acknowledgements:

The authors would like to thank the EuroTEAM Patient Research Partners Panel for their involvement in this research.

Competing interests

The authors have no conflicts of interests to declare.

Contribution statement

All authors made a substantial contribution to study conception and design. RJS, MS, ME, EM, KK collected the data. RJS analysed and interpreted data. All authors were involved in drafting the article, revising it and final approval of the version of the article to be published was given by all authors.

Introduction

Rheumatoid arthritis (RA) is a chronic destructive polyarthritis. It affects approximately 1% of the population¹ and typically manifests in the 4th and 5th decades of life.²⁻⁴ Delays in diagnosis and treatment of RA are common and are associated with worse outcomes.⁵⁻⁸ Recently, an increased research effort has been directed towards the 'at risk' phases of RA, prior to the development of clinical signs of joint swelling, to identify those at risk of developing RA and to reduce this risk through the modification of environmental risk factors and pharmacological intervention.^{9;9-11}

Genetic factors contribute significantly to the risk of RA.¹² For seropositive RA at least half of the risk is conferred by genetic risk factors¹³ with recent large genetic studies having identified over 100 susceptibility loci.^{14;15} Population based epidemiological studies have shown that having a family history of RA increases the risk of RA by approximately 3-5 times,¹⁶⁻¹⁸ with the risk being higher in first degree relatives than second degree relatives.¹⁷ Furthermore, a range of environmental and life-style risk factors including occupational exposure to pollutants,¹⁹ body mass index,²⁰ periodontitis,²¹ reproductive factors,²² smoking,²³ and dietary factors²⁴⁻²⁶ contribute to the increased risk of developing RA. Some of these environmental risk factors may interact mechanistically with genetic risk factors to increase the risk of RA,²⁷ and others may have familial associations thus contributing to the familial aggregation of RA.^{28;29}

Individuals with genetic and environmental risk factors for RA may progress through a phase associated with the development of systemic autoimmunity (e.g. the development of autoantibodies such as rheumatoid factor,^{30;31} anti-citrullinated protein / peptide antibodies and anti-carbamylated protein antibodies³²) before the clinical symptoms and signs of RA manifest.⁹ It remains unclear whether there are changes detectable within the synovium during the phase of autoantibody positivity prior to the development of joint swelling.^{33;34}

Together these data suggest that information related to genotype, environmental exposures and measures of autoimmunity and inflammation may be used to predict RA development in individuals who have not yet developed clinical disease. A potential target population for

1
2
3 such testing, with a view to risk stratification and intervention to modulate risk, are the first-
4 degree relatives of individuals with RA. Indeed a number of ongoing prospective studies are
5 recruiting the first-degree relatives of patients with RA to study disease mechanisms driving
6 the switch to RA,³⁵ to develop predictive algorithms for RA, and to test interventions to
7 reduce RA risk.³⁶ Whilst considerable research effort is thus focussed on the first-degree
8 relatives of RA patients, and a qualitative study has gathered data relating to their views of
9 preventive strategies,³⁷ little is known about how such individuals view issues related to
10 their susceptibility to and risk of developing RA, and how willing they would be to be
11 assessed and tested to have this risk quantified. The present qualitative study addresses
12 these issues.
13
14
15
16
17
18
19
20
21

22 **Methods**

23
24 Ethical approval was obtained in the UK from the HumberBridge National Research Ethics
25 Committee, in Austria from the Ethics Committee of the Medical University of Vienna and in
26 Germany from the Ethics committee of the University of Erlangen-Nuremberg.
27
28
29
30
31
32

33 **Procedure**

34
35
36 Eligible participants were the first-degree relatives (offspring and siblings) of people with
37 RA. Participants were required to be at least 18 years of age and without a diagnosis of
38 inflammatory joint disease.
39
40
41
42

43
44 Patients with RA were approached during routine secondary care clinics in Birmingham
45 (United Kingdom), Erlangen (Germany) and Vienna (Austria) and were given a letter to pass
46 on to a first-degree relative of their choosing inviting them to participate in an interview
47 about risk and predictive testing for RA. Participants were recruited between October 2014
48 and October 2015. It was explained to patients that it was entirely at their discretion
49 whether to pass on the invitation letter. All research participants (i.e. the participating first-
50 degree relatives) gave written informed consent prior to interview.
51
52
53
54
55
56
57
58
59
60

1
2
3 The semi-structured interviews were guided by an interview schedule which was informed
4 by a review of the qualitative literature exploring perceptions of risk and testing in those at
5 risk of developing a chronic disease.^{38,39} The interviews aimed to assess personal
6 perceptions of risk, therefore, one-to-one interviews were conducted. In addition, an
7 international multi-disciplinary team of healthcare professionals, patient research partners
8 and researchers working on the EuroTEAM project (www.team-arthritis.eu) reviewed and
9 redrafted the interview schedule (see table 1 for sample questions from the final interview
10 schedule).

11
12
13
14
15
16
17
18
19 **One-to-one** Interviews were conducted at local hospitals or by telephone (for those
20 participants who had difficulty in attending the hospital for a face-to-face interview).
21 Interviews lasted between 30 and 90 minutes and were digitally audio-recorded. In the UK,
22 participants who wanted further information about arthritis were advised to contact
23 Arthritis Research UK, the National Rheumatoid Arthritis Society or the local hospital's
24 Patient Advice and Liaison Service. Participants in Austria and Germany were advised to
25 contact the local rheumatology outpatient clinic.
26
27
28
29
30
31
32

33 The interviews were transcribed verbatim. Interviews conducted in German were translated
34 into English following transcription. Transcripts were anonymised and analysed centrally in
35 Birmingham, UK, by RJS.
36
37
38
39

40 ***Analysis procedure***

41 Data collection and analysis were carried out in parallel to assess when thematic saturation
42 of major developing themes had been achieved. The data were analysed using a thematic
43 approach⁴⁰ facilitated by NVivo (a qualitative software programme).⁴¹ Transcripts were
44 subjected to line-by-line coding by RJS. Patient research partners blind coded three
45 transcripts to develop reliable and inclusive themes informed by multiple perspectives.
46 Discussion of the coding framework took place between researchers and patient research
47 partners. Coding categories that lacked concordance were discussed and absorbed into the
48 coding framework. The initial codes were then grouped into the most noteworthy and
49 frequently occurring categories. The core themes extracted and presented here focus on
50
51
52
53
54
55
56
57
58
59
60

1
2
3 perceptions of first-degree relatives about their personal risk of RA and their views on being
4 tested.
5
6

7 8 **Results** 9

10
11 Thirty-four first-degree relatives of patients with RA participated, 24 from the UK, 3 from
12 Germany and 7 from Austria. Six participants were siblings of an RA patient, 26 were the
13 adult offspring an RA patient and 2 participants had both a sibling and a parent with RA.
14 Participants were aged between 23 and 67 years (mean 39 years) and 26 (76%) were female
15 (see table 2 for participant characteristics). Quotations are presented in tables 3, 4, 5 and 6
16 and are referred to in the text using “Q” followed by the quotation code.
17
18
19
20
21
22

23 24 **Understanding of family history and genetic factors as risk factors for RA** 25

26
27 The first-degree relatives of people with RA understood that there was a hereditary
28 component to RA (Q1), and often used the word “genetic” to describe the cause of their
29 increased risk (Q2). First-degree relatives (from here on referred to as “relatives”)
30 recognised that they were more susceptible to developing RA than second-degree relatives
31 (Q3). Interestingly, some felt that they were more susceptible to developing RA than other
32 first-degree relatives because they appeared to follow other patterns of illness displayed by
33 their relative with RA (Q4). Additional biological factors, such as being female and some
34 environmental factors were also described as playing a role in the development of RA
35 (Q2&5).
36
37
38
39
40
41
42

43
44 When considering their perceived personal susceptibility, relatives reported that there were
45 aspects of familial risk, particularly genetic susceptibility, which they found difficult to
46 understand. One relative felt that effectively communicating an understanding of genetic
47 risk to the public was extremely challenging (Q6). Others felt that they needed more
48 information about their level of risk as a relative and the specific role that genes associated
49 with RA played in this risk (Q7).
50
51
52
53
54
55
56
57
58
59
60

1
2
3 When considering their susceptibility to RA, relatives voiced their concerns about the future,
4 and how being at risk of developing RA was a worry for them. Those who had considered
5 their personal susceptibility to RA, described being fearful of what they may uncover if they
6 were to have their risk quantified. For some, the prospect of living with RA would entail
7 great amounts of uncertainty (Q8). For many, having witnessed the impact of RA on their
8 sibling / parent, heightened the worry they felt in relation to the possibility of developing RA
9 themselves in the future (Q9). Interestingly, a small number of relatives had experienced
10 joint related symptoms but had not yet sought medical advice, being fearful of the potential
11 outcome (Q10).
12
13
14
15
16
17
18
19
20
21

22 **Personal considerations of RA risk and communication about risk within families**

23
24 Relatives discussed knowing little about RA or its risk factors, feeling that they had been
25 “shielded” or “protected” from this knowledge by their sibling / parent (Q11). Also, relatives
26 described how they rarely discussed RA within their family unit, and in some cases the
27 invitation to participate in this study was the first time that the opportunity to discuss RA,
28 and its risk had emerged (Q12). For one relative, receiving the invitation to take part in this
29 study facilitated the first conversation he had had with his father about RA (Q13). Another
30 described how his mother had had some concerns about him taking part in this study,
31 because of the worry which discussing issues surrounding risk and predictive testing may
32 cause (Q14). One relative described how her brother had been asked to take part in this
33 study, but ignored the request; her mother had then approached her and encouraged her to
34 participate (Q15). This relative suggested that it was her attitude towards health which set
35 her apart from her brother.
36
37
38
39
40
41
42
43
44
45

46 Most relatives had not fully considered issues related to their personal susceptibility to RA
47 prior to being approached to take part in this study (Q16). Some relatives indicated that
48 taking part in this study had been a positive experience for them and had provided them
49 with much needed knowledge, a chance for reflection on their risk and a greater
50 understanding of RA and how it affected their sibling / parent (Q17). However, others
51 described how they would prefer to avoid considering their personal risk of RA to avoid
52 experiencing worry or anxiety about the future (Q18).
53
54
55
56
57
58
59
60

Perceptions surrounding the use of predictive tests: positive perspectives

Most relatives were in favour of the basic principle behind predictive testing - identifying those at risk and quantifying the level of risk (Q19). It was also felt that the information gained from predictive testing could be acted upon to reduce the future risk of developing RA (Q20). In particular, relatives recognised the importance of early intervention, and were aware that testing could put them “on alert” for the early symptoms of RA (Q21), or suggested that they might be able to take preventive treatment (Q22). Many relatives felt that it was important to know that they were at risk, and that information related to their actual risk would be of value to them, allowing them to “mentally” prepare for the future (Q23). Others could see the benefit of preparing for the functional limitations that may be associated with RA (Q24). A few had already undertaken predictive testing to explore their personal risk of developing RA (Q25). Some were willing to be tested for altruistic reasons such as taking part in research (Q26).

Perceptions surrounding the use of predictive tests: negative perspectives

The ability of predictive tests to quantify risk was widely discussed (Q27), with one participant questioning the specificity and sensitivity of the test (Q28). Relatives expressed a desire for tests that would, with a very high likelihood, be able to confirm or exclude the fact that they would develop RA (Q29). However, many relatives suspected that test results would give them an intermediate risk of developing RA and others highlighted concerns about “false positive” results (Q30). Some believed that predictive testing would not be able to give them answers to questions they thought were important for example how severe would their RA be were they to develop it, and when it would be most likely to begin (Q31).

Relatives were worried about the impact of testing on their family members and in particular on their sibling / parent with RA (Q32). Participants felt that by seeking information about risk and pursuing testing that they would cause their relative with RA to experience stress, worry or feelings of guilt. Participants were further worried about the stress that predictive test results may cause them. One even suggested that such stress could cause the disease to develop earlier than it otherwise would (Q33).

1
2
3
4
5
6 Relatives felt that being given risk information when they were young would be a particular
7 burden (Q34). Instead, they felt that testing should be left until later in life, when the
8 chance of developing a condition like RA was higher. Risk information was considered to
9 have significant implications for future life choices and could make them “rush” though life
10 (Q35). One relative suggested such information could bring forward major life decisions, such
11 as having children (Q36).
12
13
14
15
16

17
18 Some relatives reflected upon previous negative personal experiences of having received
19 poorly communicated test related information (Q37). For some, the approach to the
20 delivery of risk information represented an important feature of a predictive test, and may
21 determine whether the test would be acceptable to them. Relatives discussed how they
22 would want to be told prior to the test what format the result would take. Some suggested
23 that they would like to receive the results by letter, and then be given the opportunity to
24 discuss the results with a healthcare professional (Q38). Other relatives emphasized the
25 importance of talking to someone about the test result, especially to manage the
26 psychological distress that may be associated with receiving a “positive” test result (Q39).
27 Many relatives felt that there was a need for ongoing support from a healthcare
28 professional following testing (Q40).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

This study explored the degree to which first-degree relatives of people with RA felt that they were susceptible to developing RA and their perceptions of predictive testing. Most relatives were aware that there was a genetic contribution to the risk of RA, and that they may be susceptible to developing RA; however they were unsure of the extent of the additional risk. Relatives highlighted the need for additional information about familial risk and described the need for better communication strategies in relation to imparting this information.

Generally, first-degree relatives felt that there was a need for more information and support specifically designed for the family members of people with RA. The current lack of support and information was suggested to have a number of effects, including family members not feeling able to communicate and support the person affected with RA and not feeling able to understand concepts surrounding the nature of RA and the risks associated with RA. Studies of information sharing amongst family members at risk of cancer have found that patients with the disease do not always communicate risk information in a timely or thorough fashion.⁴² Forrest et al found that relatives from smaller families, and female relatives were more likely to make contact with genetic services.⁴³ Research has shown that genetic counselling can facilitate interfamily communication, and can help to minimize distress and increase the number of family members making contact with health services to be tested.^{44;45}

An incidental finding of this research was that being invited to take part in research about risk was the first time that some relatives had fully considered their personal susceptibility to RA. In some cases this exposure was viewed positively but in other cases it caused worry and concern. It is difficult to draw conclusions about the specific impact taking part in this study had on relatives' well-being but we note that relatives did indicate that support mechanisms would be helpful to enable them to understand and cope with risk related information, especially if predictive testing were to be offered. We would suggest that

1
2
3 researchers accessing participants in “at risk” populations pay particular attention to the
4 impact that an invitation to participate and participation itself may have, and offer
5 additional support to mitigate against anxiety caused. While personal susceptibility may not
6 have been considered, perceptions of RA severity may predict personal willingness to
7 engage in predictive testing. It is possible that first degree relatives of people with more
8 severe forms of RA or poorly controlled disease maybe more motivated to engage in
9 predictive testing. This would be in line with the predictions of the health belief model.⁴⁶ A
10 quantitative investigation to assess the effect of factors such as disease severity in people
11 with RA, on their family members’ perceptions of risk and orientation towards predictive
12 testing is needed to test this hypothesis.
13
14
15
16
17
18
19
20

21
22 In addition, it became apparent during the course of this study that some relatives were
23 symptomatic but had not yet sought medical help. Detailed information on the health status
24 of the participating relatives was not gathered within this study but those who were
25 symptomatic were advised to speak to their family physician, and were given details of
26 resources for obtaining additional information. However, the symptomatic nature of some
27 relatives raises important issues surrounding informing relatives about risk, and the
28 importance of seeking help quickly should symptoms emerge. While some relatives were
29 aware that their symptoms may be indicative of the early stages of RA, and were worried
30 about what information would be revealed to them if they sought help, few were aware of
31 the importance of early intervention. Were information about the benefits of early
32 intervention in preventing joint destruction made available to them, it is possible that their
33 attitude to help seeking may have been different.
34
35
36
37
38
39
40
41
42
43
44

45 This study has a number of limitations. Firstly, our access to first-degree relatives was via
46 patients with RA. Some relatives described how they were chosen in preference to other
47 relatives, who would either worry too much or not be receptive to discussing issues related
48 to risk. The findings presented here may thus not fully reflect the range of views related to
49 risk and testing held by first-degree relatives. This potential limitation highlights the need to
50 fully understand the barriers that patients with RA face when discussing issues of risk with
51 family members. A second limitation of this research was that the majority of participants
52 were female. A criticism of many qualitative studies in the field of RA is that the male
53
54
55
56
57
58
59
60

1
2
3 perspective is underrepresented.⁸ While the female: male ratio of RA is typically 2:1 it is
4 essential that studies attempt to include the views of more male participants. **Therefore, we**
5 **acknowledge that themes related to gender and male perspectives of risk and predictive**
6 **testing did not reach saturation and are not represented in our data.** A final limitation is that
7 only a small number of individuals from ethnic-minority communities were interviewed,
8 therefore, a full understanding of the cultural barriers to predictive testing was not
9 achieved.

10
11 Besides these limitations, this study has a number of strengths. Relatives were sampled
12 from centres in 3 different European countries and saturation of the main themes was
13 achieved by combining interview data from all centres; furthermore, no differences in the
14 views expressed by relatives sampled from different European countries were detected.
15 Gathering data from multiple countries means that interventions developed based on these
16 data are likely to be relevant in multiple contexts. A further strength of this study was the
17 support given by an international panel of patient research partners who advised
18 researchers and acted as co-researchers.

19
20 Identifying individuals at risk of RA may allow targeted interventions to reduce the risk and
21 consequence of future disease; however, our data show that relatives have concerns about
22 predictive testing and risk information that would result from it **(the key messages of this**
23 **study are summarised in tabled 7).** The future development of strategies to quantify and
24 communicate risk needs to take these views into account and incorporate approaches to
25 mitigate concerns and minimize any negative psychological impact of risk information.

26 27 28 **Data Sharing Statement**

29
30 Unpublished data is available in the form of unanalysed interview transcripts sorted in an
31 NVIVO file from the corresponding author. Data can be obtained by emailing the
32 corresponding author.

Reference List

- (1) Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. *Rheumatology (Oxford)* 2002; 41(7):793-800.
- (2) Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. *Arthritis Rheum* 1998; 41(5):778-799.
- (3) Stack RJ, Shani M, Mallen CD, Raza K. Symptom complexes at the earliest phases of rheumatoid arthritis: a synthesis of the qualitative literature. *Arthritis Care Res* 2013; 65(12):1916-1926.
- (4) Stack RJ, van Tuyl LH, Sloots M, van de Stadt LA, Hoogland W, Matt B et al. Symptom complexes in patients with seropositive arthralgia and in patients newly diagnosed with rheumatoid arthritis: A qualitative exploration of symptom development. *Rheumatology (Oxford)* 2014; 53(9):1646-1653.
- (5) Chan KWA, Felson DT, Yood RA, Walker AM. The Lag Time Between Onset of Symptoms and Diagnosis (Dx) of Rheumatoid-Arthritis (Ra) and Its Determinants. *Arthritis and Rheumatism* 1992; 35(9):S125.
- (6) Kiely P, Williams R, Walsh D, Young A. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. *Rheumatology (Oxford)* 2009; 48(1):57-60.
- (7) Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. *Rheumatology (Oxford)* 2004; 43(7):906-914.
- (8) Stack RJ, Shaw K, Mallen C, Herron-Marx S, Horne R, Raza K. Delays in help seeking at the onset of the symptoms of rheumatoid arthritis: a systematic synthesis of qualitative literature. *Ann Rheum Dis* 2012; 71(4):493-497.
- (9) Gerlag DM, Raza K, van Baarsen LG, Brouwer E, Buckley CD, Burmester GR et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. *Ann Rheum Dis* 2012; 71(5):638-641.
- (10) Karlson EW, van SD, van der Helm-van Mil AH. Strategies to predict rheumatoid arthritis development in at-risk populations. *Rheumatology (Oxford)* 2014.
- (11) Raza K, Filer A. Predicting the development of RA in patients with early undifferentiated arthritis. *Best Pract Res Clin Rheumatol* 2009; 23(1):25-36.
- (12) Yarwood A, Huizinga TW, Worthington J. The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. *Rheumatology (Oxford)* 2014.

- 1
2
3 (13) MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K et al.
4 Characterizing the quantitative genetic contribution to rheumatoid arthritis using data
5 from twins. *Arthritis Rheum* 2000; 43(1):30-37.
6
7 (14) Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K et al. Genetics of rheumatoid
8 arthritis contributes to biology and drug discovery. *Nature* 2014; 506(7488):376-381.
9
10 (15) Kim K, Bang SY, Lee HS, Cho SK, Choi CB, Sung YK et al. High-density
11 genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid
12 arthritis risk loci. *Ann Rheum Dis* 2015; 74(3):e13.
13
14 (16) Somers EC, Antonsen S, Pedersen L, Sorensen HT. Parental history of lupus and
15 rheumatoid arthritis and risk in offspring in a nationwide cohort study: does sex
16 matter? *Ann Rheum Dis* 2013; 72(4):525-529.
17
18 (17) Grant SF, Thorleifsson G, Frigge ML, Thorsteinsson J, Gunnlaugsdottir B, Geirsson
19 AJ et al. The inheritance of rheumatoid arthritis in Iceland. *Arthritis Rheum* 2001;
20 44(10):2247-2254.
21
22 (18) Frisell T, Holmqvist M, Kallberg H, Klareskog L, Alfredsson L, Askling J. Familial
23 risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-
24 citrullinated protein antibody status, number and type of affected relatives, sex, and
25 age. *Arthritis Rheum* 2013; 65(11):2773-2782.
26
27 (19) Too CL, Muhamad NA, Ilar A, Padyukov L, Alfredsson L, Klareskog L et al.
28 Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results
29 from a Malaysian population-based case-control study. *Ann Rheum Dis* 2015.
30
31 (20) Qin B, Yang M, Fu H, Ma N, Wei T, Tang Q et al. Body mass index and the risk of
32 rheumatoid arthritis: a systematic review and dose-response meta-analysis. *Arthritis
33 Res Ther* 2015; 17:86.
34
35 (21) Chou YY, Lai KL, Chen DY, Lin CH, Chen HH. Rheumatoid Arthritis Risk
36 Associated with Periodontitis Exposure: A Nationwide, Population-Based Cohort
37 Study. *PLoS One* 2015; 10(10):e0139693.
38
39 (22) Orellana C, Saevarsdottir S, Klareskog L, Karlson EW, Alfredsson L, Bengtsson C.
40 Postmenopausal hormone therapy and the risk of rheumatoid arthritis: results from the
41 Swedish EIRA population-based case-control study. *Eur J Epidemiol* 2015;
42 30(5):449-457.
43
44 (23) Stoll T, Gordon C, Seifert B, Richardson K, Malik J, Bacon PA et al. Consistency and
45 validity of patient administered assessment of quality of life by the MOS SF-36; its
46 association with disease activity and damage in patients with systemic lupus
47 erythematosus. *J Rheumatol* 1997; 24(8):1608-1614.
48
49 (24) Pattison DJ, Silman AJ, Goodson NJ, Lunt M, Bunn D, Luben R et al. Vitamin C and
50 the risk of developing inflammatory polyarthritis: prospective nested case-control
51 study. *Ann Rheum Dis* 2004; 63(7):843-847.
52
53
54
55
56
57
58
59
60

- 1
2
3 (25) Pattison DJ, Symmons DP, Lunt M, Welch A, Luben R, Bingham SA et al. Dietary
4 risk factors for the development of inflammatory polyarthritis: evidence for a role of
5 high level of red meat consumption. *Arthritis Rheum* 2004; 50(12):3804-3812.
6
7 (26) Rosell M, Wesley AM, Rydin K, Klareskog L, Alfredsson L. Dietary fish and fish oil
8 and the risk of rheumatoid arthritis. *Epidemiology* 2009; 20(6):896-901.
9
10 (27) Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J et al. A
11 new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR
12 (shared epitope)-restricted immune reactions to autoantigens modified by
13 citrullination. *Arthritis Rheum* 2006; 54(1):38-46.
14
15 (28) Sparks JA, Chang SC, Liao KP, Lu B, Fine AR, Solomon DH et al. Rheumatoid
16 arthritis and mortality among women during 36 years of prospective follow-up:
17 Results from the Nurses' Health Study. *Arthritis Care Res (Hoboken)* 2015.
18
19 (29) Sparks JA, Chen CY, Jiang X, Askling J, Hiraki LT, Malspeis S et al. Improved
20 performance of epidemiologic and genetic risk models for rheumatoid arthritis
21 serologic phenotypes using family history. *Ann Rheum Dis* 2015; 74(8):1522-1529.
22
23 (30) Aho K, Palosuo T, Raunio V, Puska P, Aromaa A, Salonen JT. When does
24 rheumatoid disease start? *Arthritis Rheum* 1985; 28(5):485-489.
25
26 (31) Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et
27 al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict
28 the development of rheumatoid arthritis. *Arthritis Rheum* 2003; 48(10):2741-2749.
29
30 (32) Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van SD et al. Anti-
31 carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis.
32 *Ann Rheum Dis* 2014; 73(4):780-783.
33
34 (33) de Hair MJ, van de Sande MG, Ramwadhoebe TH, Hansson M, Landewe R, van der
35 Leij C et al. Features of the synovium of individuals at risk of developing rheumatoid
36 arthritis: implications for understanding preclinical rheumatoid arthritis. *Arthritis*
37 *Rheumatol* 2014; 66(3):513-522.
38
39 (34) Gent YY, Voskuyl AE, Kloet RW, van SD, Hoekstra OS, Dijkmans BA et al.
40 Macrophage positron emission tomography imaging as a biomarker for preclinical
41 rheumatoid arthritis: findings of a prospective pilot study. *Arthritis Rheum* 2012;
42 64(1):62-66.
43
44 (35) Ferucci ED, Darrach E, Smolik I, Choromanski TL, Robinson DB, Newkirk MM et al.
45 Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid
46 arthritis and unaffected first-degree relatives in indigenous North American
47 Populations. *J Rheumatol* 2013; 40(9):1523-1528.
48
49 (36) Sparks JA, Iversen MD, Kroouze RM, Mahmoud TG, Triedman NA, Kalia SS et al.
50 Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study:
51 Rationale and design for a randomized controlled trial evaluating rheumatoid arthritis
52 risk education to first-degree relatives. *Contemporary Clinical Trials* 2014;
53 39(1):145-157.
54
55
56
57
58
59
60

- 1
2
3 (37) Novotny F, Haeny S, Hudelson P, Escher M, Finckh A. Primary prevention of
4 rheumatoid arthritis: a qualitative study in a high-risk population. *Joint Bone Spine*
5 2013; 80(6):673-674.
6
7 (38) Bayliss K, Raza K, Simons G, Falahee M, Hansson M, Starling B et al. Perceptions of
8 predictive testing for those at risk of developing a chronic inflammatory disease: a
9 meta-synthesis of qualitative studies. *Journal of Risk Research*. In press 2016.
10
11 (39) Falahee M, Simons G, Raza K, Stack RJ. Healthcare professionals' perceptions of risk
12 in the context of genetic testing for the prediction of chronic disease: A qualitative
13 metasynthesis. *Journal of Risk Research*. In press 2016.
14
15 (40) Guest GS, MacQueen KM, Namey EE. *Applied Thematic Analysis*. Thousand Oaks,
16 California: Sage Publications; 2012.
17
18 (41) NVivo qualitative data analysis software; QSR International Pty Ltd. Version 8 [
19 2008].
20
21 (42) Forrest LE, Curnow L, Delatycki MB, Skene L, Aitken M. Health first, genetics
22 second: exploring families' experiences of communicating genetic information. *Eur J*
23 *Hum Genet* 2008; 16(11):1329-1335.
24
25 (43) Forrest L, Delatycki M, Curnow L, Gen CM, Skene L, Aitken M. An audit of clinical
26 service examining the uptake of genetic testing by at-risk family members. *Genet Med*
27 2012; 14(1):122-128.
28
29 (44) Forrest LE, Burke J, Bacic S, Amor DJ. Increased genetic counseling support
30 improves communication of genetic information in families. *Genet Med* 2008;
31 10(3):167-172.
32
33 (45) Forrest LE, Delatycki MB, Skene L, Aitken M. Communicating genetic information
34 in families--a review of guidelines and position papers. *Eur J Hum Genet* 2007;
35 15(6):612-618.
36
37 (46) Rollins BL, Ramakrishnan S, Perri M. Direct-to-consumer advertising of predictive
38 genetic tests: a health belief model based examination of consumer response. *Health*
39 *Mark Q* 2014; 31(3):263-278.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Sample interview schedule for those at risk of developing RA

- Tell me what you know about RA?

PROMPTS: What do you think the causes of RA could be? What do you think the risks factors for RA are? Tell me about how serious you think RA is? How would you know you had RA e.g what symptoms would you expect? What would be the impact of RA on your life? Do you think you would be able to control RA yourself? Do you think there are treatments available that would effectively treat RA?

- Do you ever worry about the possibility of developing RA in the future?
- What would you think if you were told that you could have a test that would tell you how likely you were to develop RA?

PROMPTS: What sort of information should this test give you? When do you think would be the right time to get this information? How would you feel about the idea of having a test that would tell you your chance of developing RA in the future? In what ways do you think it would be helpful for you to know your chances of developing RA?

- What would your concerns be if you knew what your risk of developing RA was?
- What kind of tests do you think people might be able to do to work out whether or not you might develop RA (test that are available now and tests that might become available in the future)?

Table 2: Details of first degree relatives of RA patients who participated in the interviews

Participant no.	Gender	Age	Ethnicity	Relation to RA patient	Experience of testing	Self-reported musculoskeletal symptoms	Interview country
Participant 1	Female	36	White British	Daughter	None	None	UK
Participant 2	Female	42	White British	Daughter	None	Previous septic arthritis	UK
Participant 3	Male	35	White British	Son	None	None	UK
Participant 4	Male	67	White British	Brother	None	None	UK
Participant 5	Male	31	White British	Son	Reports having had a “genetic test” for RA (performed by family physician).	None	UK
Participant 6	Female	23	White British	Daughter	None	None	UK
Participant 7	Female	30	White British	Daughter	None	Ankle pain and intermittent ankle swelling attributed by patient to a previous “ankle dislocation”	UK
Participant 8	Female	39	White British	Daughter	Rheumatoid factor	Elbow pain	UK

previously

measured

Participant 9	Female	54	White British	Sister	None	Finger pain	UK
--------------------------------	--------	----	------------------	--------	------	-------------	----

Participant 10	Female	35	White British	Daughter	None	“Inflamed knee” during pregnancy	UK
---------------------------------	--------	----	------------------	----------	------	--	----

Participant 11	Female	44	White British	Sister AND Daughter	None	Back pain	UK
---------------------------------	--------	----	------------------	---------------------------	------	-----------	----

Participant 12	Female	44	White British	Sister	None	Finger pain	UK
---------------------------------	--------	----	------------------	--------	------	-------------	----

Participant 13	Female	41	White British	Sister AND Daughter	Rheumatoid factor previously measured by family physician	Finger pain, stiffness and swelling	UK
---------------------------------	--------	----	------------------	---------------------------	--	---	----

Participant 14	Female	60	White	Daughter	Has had “blood tests” (participant unsure which)	Has a diagnosis of osteoarthritis	UK
---------------------------------	--------	----	-------	----------	---	--------------------------------------	----

Participant 15	Female	29	White British	Daughter	None	None	UK
---------------------------------	--------	----	------------------	----------	------	------	----

Participant 16	Female	40	White British	Daughter	None	None	UK
Participant 17	Female	41	Asian (UK born)	Daughter	None	None	UK
Participant 18	Female	28	White British	Daughter	None	None	UK
Participant 19	Male	42	Chinese	Son	None	None	UK
Participant 20	Female	25	White British	Daughter	None	None	UK
Participant 21	Female	41	White British	Daughter	None	Had previous joint swelling in wrists and hands	UK
Participant 22	Female	32	White British	Sister	None	None	UK
Participant 23	Female	44	White British	Daughter	None	None	UK
Participant 24	Male	47	White British	Son	None	None	UK
Participant 25	Female	29	White German	Daughter	None	None	Germany

Participant	Female	37	White	Daughter	None	None	Germany
26			German				
Participant	Female	51	White	Daughter	None	None	Germany
27			German				
Participant	Female	21	White	Daughter	None	None	Austria
28			Austrian				
Participant	Male	33	White	Son	None	None	Austria
29			Austrian				
Participant	Female	65	White	Sister	None	None	Austria
30			Austrian				
Participant	Female	36	White	Sister	Reports	None	Austria
31			Austrian		having had a blood test		
Participant	Male	37	White	Son	None	None	Austria
32			Austrian				
Participant	Male	37	White	Son	None	None	Austria
33			Austrian				
Participant	Female	33	White	Daughter	None	None	Austria
34			Austrian				

Table 3 Quotations related to an understanding of family history and genetic factors as risk factors for rheumatoid arthritis

Code	Quotation
Q1	<i>"I see that my mother has it and I'm just worried that it might be passed on to me or my sister or other members of my family." (Participant 19)</i>
Q2	<i>"In my opinion it's environmental factors or genetics." (Participant 28)</i>
Q3	<i>"So I know it's blood-related... I think if it was your cousin or your aunt there'd be a slim chance..... being direct blood-related, I would class myself as, or think of myself that I am at a higher risk than most." (Participant 6)</i>
Q4	<i>"I seem to follow my mum in absolutely everything, like my brother and sister they're quite like my dad, they never get ill, they never catch a cold. Whereas if there's a cold going around I will get it and the same with my mum... So I was a bit like 'oh, maybe I'll get it'." (Participant 18)</i>
Q5	<i>"I know that there's a genetic tendency. That it runs in families. I'm female, so I'm more at risk because I'm female... I know first degree relative increases your risk, so yeah, it does worry me." (Participant 10)</i>
Q6	<i>"Genetics really worry me because I don't know anything about them and I think when people think of genetics they think of like I don't know it's quite like a complicated thing that we're never going to understand because there's no simple way of putting it.... But like your average Joe Bloggs [average person] isn't going to know extensive information about your genes." (Participant 20)</i>
Q7	<i>"For me personally it's kind of hard facts and figures; I'm more comfortable knowing in terms of percentages. I know my dad has got rheumatoid arthritis, and if you've got a hard fact and figure to say that the chances of a close relative, son or daughter, developing rheumatoid arthritis at some point in their life then that information would be useful to me." (Participant 5)</i>
Q8	<i>"It [life] wouldn't be predictable anymore; I wouldn't know how things would be from one day to the next, or in an hour's time, when I woke up the next morning, wondering what the day would bring. I think it's pretty serious, it restricts your everyday life. And it differs – my father has pain and sometimes it's there,</i>

	<i>sometimes it's not; it's unpredictable." (Participant 25)</i>
Q9	<i>"I do worry about it, yeah, because I don't want to end up developing anything like that. I like to keep busy and I don't want to be restricted. It is a big worry, yeah. I don't want to go through what my mum's going through at the moment, because she's been through a lot." (Participant 13)</i>
Q10	<i>"I've got pain down my left leg [okay], but I just don't know whether it's sciatica, or whether it could be something linked to arthritis, but I'm too frightened to go and have a scan. So I probably do need it to find that. I'm just putting it off." (Participant 15)</i>

Table 4 Quotation related to personal considerations of rheumatoid arthritis risk and communication about risk within families

Code	Quotation
Q11	<i>"That's exactly what he doesn't talk to me about, he's the kind of person who leaves others out of it, deals with it by himself." (Participant 30)</i>
Q12	<i>"I am worried about that...I was quite surprised when mum said that she'd had this letter explaining about the research that you're doing." (Participant 23)</i>
Q13	<i>"He doesn't tend to talk about it. He didn't want to ask me to do this phone call, but forced himself to one day...This is probably the first time he's actually asked me to do anything and he was clearly uncomfortable." (Participant 24)</i>
Q14	<i>"I never had that information of what happens, how you're made at higher risk, I've never had that in like black and whitewhich makes me think she doesn't know or maybe she's just trying to protect me like a mother does. Because I think she was quite worried about me taking part....she's quite worried about what I'd find out. (Participant 5)</i>
Q15	<i>"My mum, sort of, mentioned this to him [brother], and he was just, like, ignored the fact that she'd said anything to me. And then she came to me and said, 'I thought I'd ask your brother first but he won't,' and I said, 'I don't mind,' but he's probably different to me, just blissful ignorance, whereas I'm probably a little bit different." (Participant 2)</i>
Q16	<i>"Up until now I have never thought about it, what that would be like, whether it might happen" (Participant 28)</i>
Q17	<i>"I guess before we spoke I couldn't understand what it was exactly that was making her finger sore or swollen or anything like that. I would just be like, drink more milk." (Participant 20)</i>
Q18	<i>"You only worry too much and rack your brain, because then I have to consider that my children could get it too and then you would worry too much. It's more comfortable to avoid it." (Participant 32,)</i>

Table 5 Quotations related to perceptions surrounding the use of predictive tests: positive perspectives

Code	Quotation
Q19	<i>"I'm open to everything, well, I don't know why I shouldn't have that done, I couldn't think of a reason off the top of my head not to do it." (Participant 31)</i>
Q20	<i>"If I was offered a test, I'd be very happy to have one. I don't need to think about that. Well, it might be if it might help me combat a disease later, or at least know how to treat it. Well, if I'm at risk I think it would be helpful to know." (Participant 3)</i>
Q21	<i>"I would do that straight away, because I want to know as soon as possible, because I think the more you know the earlier, the more you can do about it." (Participant 31)</i>
Q22	<i>"I think that with kind of information, I'd be more keen to, sort of, sort out what I needed to do to try and prevent that becoming a problem. If I could take some sort of medication to...head it off before it became a big problem." (Participant 2)</i>
Q23	<i>"I think that would be a good thing. I think I'd like to know because then I may be able to prepare a bit more, like mentally as well." (Participant 20)</i>
Q24	<i>"Yes, it would. I think I would have the test just to see what the long-term forecast is, because my job's fairly labour intensive. I'd be willing to know what the future holds, just from the point of view of my job circumstances at work." (Participant 19)</i>
Q25	<i>"Actually I did get tested, but it was a long time ago." (Participant 27)</i>
Q26	<i>"I'm not averse to having them, especially, if it helps with research and stuff like that." (Participant 2)</i>

**Table 6 Quotations related to perceptions surrounding the use of predictive tests:
negative perspectives**

Code	Quotation
Q27	<i>"Exactly, if it is only a vague presumption where they say, yes, you could perhaps out of two to five people or something, you could get it and the others wouldn't, well that is very vague. (Participant 32)</i>
Q28	<i>"That depends on the test, how specified it is and how sensitive it is, otherwise I would not have the test done." (Participant 29)</i>
Q29	<i>"Because if told me – it's only how likely, it's not a, 'You will develop it,' and it doesn't tell you when you will develop it. So I think if somebody said to me, 'There's this test out there and it'll tell you whether you might develop it,' I wouldn't want it, because you could just live your life in fear and never actually develop it. So unless it was 100% guaranteed, and somebody could say, 'You will develop it within this time frame,' I don't wanna [want to] spend the next 30 years worrying about something, when I could be enjoying those 30 years. So, no, I'd probably – it depends on the exact details of the test. (Participant 10)</i>
Q30	<i>"Or, equally, I guess, false positive. If you've got one really bad, sort of, joint that you've tested, it could, kind of, put a bit of a negative spin on it." (Participant 1)</i>
Q31	<i>"It would be nice to know when ... at what point in time you were going to get ill, and how severe it was going to be ... but I don't know whether a test can find that out. (Participant 25)</i>
Q32	<i>"But I wouldn't want to worry my mum by saying, can you get me a leaflet on testing. I wouldn't want my mum to worry that I was going for this test....to know that if in five years time I'll get it, I don't want her to know that because I think that would worry her more than anything." (Participant 6)</i>
Q33	<i>"On the one hand you know that you might develop the disease and it is of course stressful, because then you know, one day, when I'm about 30 – 40 years old, it will start and then my body will become weaker and I will get this disease, then it could create a lot of stress to have these negative thoughts. I don't know what the psychological effect would be on the body, whether it really might break out</i>

	<i>sooner. If you don't know, so, if you say, I don't know and you live each day as it comes, meaning that it might break out at a later date." (Participant 32)</i>
Q34	<i>"From personal experience, I think it would be something that when I got a bit older and certain things started going wrong with me or I started getting more illnesses I'd think I'd need to start looking to what all these problems are. At this particular moment in time, when there's generally nothing wrong with me, I just think that I don't really need to delve too much into that sort of information."(Participant 4)</i>
Q35	<i>"Yeah I kind of wouldn't want this test to tell me that I had a 50/50 chance of getting it in the next five years because that would change my entire perception on what I wanted. And I guess if someone gave me that bit of information I'd have to seriously think, well maybe I can't have that, maybe I've got to like push everything forward like get married and have kids before I start to take medication which I guess that's a lot of information I don't know about in that if I had to start taking that medication would that affect me having kids. It's like knowing when you're going to die that doesn't sit right with me either." (Participant 15)</i>
Q36	<i>"I think, if, for argument's sake, I'd gone for the test tomorrow, and the results came back and they said, 'Yeah, you're at high risk,' and in two years' time, the symptoms kicked in, you're then thinking, 'Right, okay.' We'd probably want a second child and we'd want a third, 'Let's do it now,' sort of, thing, but otherwise, I think, you know, just life would carry on" (Participant 6,)</i>
Q37	<i>"The GP [family physician] literally just sat me down, blurted some technical words out, medical terminology to me that went straight over my head and, again, didn't sink. I think, just keep simple, instead of baffling people with medical science, really, of your technical words that you use, compared to what, sort of, the general public are going to understand." (Participant 6)</i>
Q38	<i>"I'd be happy, I think, if, before the test, someone would explain the kind of outcome to expect. And then when I got the test results back, it would be okay by post, as long as there was, kind of, accompanying information. I suppose at that point you'd probably end up going to see someone anyway to talk through what tablets or whatever you could take." (Participant 1)</i>

Q39	<i>"I suppose it would be sensible to go and talk to somebody about it. (Participant 3)</i>
Q40	<i>"I think it's a good idea to talk to somebody and find out more information. I think seeing somebody on a regular basis, like every year or something, might be good if you knew that you were going to get it. Obviously, you're going to have more and more questions, aren't you? Yeah, for an update and just to see how things are going. Obviously, as time goes on, you're going to have more questions and so I think it would be good to speak to somebody." (Participant 20)</i>

Table 7: Key messages

1. Identifying those at risk of RA, and quantifying their risk, may help guide targeted interventions to reduce future disease burden. This qualitative study found that first-degree relatives of people with RA, who are themselves at an enhanced risk of RA, had a number of concerns in relation to predictive testing.
2. Some relatives would be unwilling to undergo predictive testing and were worried about the psychological impact of risk information. Others were more receptive and recognized that such information could facilitate the development and implementation of preventive strategies as well as encouraging prompt help-seeking and intervention at the onset of RA symptoms.
3. Developing strategies which communicate risk information effectively while reducing the psychological burden associated with this information is essential.